Cor Vasa 2011, 53(8-9):454-460 | DOI: 10.33678/cor.2011.114
Pheochromocytoma - tumor interesting also for cardiologists
- 1 Centrum pro výzkum, diagnostiku a léčbu arteriální hypertenze, III. interní klinika, Všeobecná fakultní nemocnice a 1. lékařská fakulta Univerzity Karlovy, Praha, Česká republika
- 2 Ústav biologie a lékařské genetiky, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice, Praha, Česká republika
Pheochromocytomas and functional paragangliomas are catecholamine-producing tumors which present typical paroxysmal symptoms (headache, palpitations, sweating and hypertension). Biochemical testing for pheochromocytoma is performed by using measurement of metanephrines in either plasma or urine not only in subjects with clinical suspicion of pheochromocytoma but also in subjects with incidentally discovered adrenal mass or in subjects with genetic predisposition for pheochromocytoma and paraganglioma. To localize pheochromocytoma, computed tomography (less frequently magnetic resonance imaging) and functional imaging with [123I]-metaiodobenzylguanidine are used. Medical pre-treatment is essential for successful tumor removal which is performed mostly by minimal invasive surgery. Long-term follow-up is mandatory due to possible tumor recurrence. Metastatic pheochromocytoma still remains a therapeutic challenge.
Keywords: Pheochromocytoma; Functional paraganglioma; Endocrine hypertension
Published: August 1, 2011 Show citation
References
- Karagiannis A, Mikhailidis DP, Athyros VG, et al. Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer 2007;14:935-956.
Go to original source...
Go to PubMed...
- Widimský J, Jr. Recent advances in the diagnosis and treatment of pheochromocytoma. Kidney Blood Press Res 2006;29:321-326.
Go to original source...
Go to PubMed...
- Zelinka T, Widimský J, jr. Endokrinní hypertenze. In: Widinský J (ed): Hypertenze. Praha: Triton, 2008:639-666
- Kopetschke R, Slisko M, Kilisli A, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol 2009;161:355-361.
Go to original source...
Go to PubMed...
- Chrisoulidou A, Kaltsas G, Ilias I, et al. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007;14:569-585.
Go to original source...
Go to PubMed...
- Fliedner SMJ, Lehnert H, Pacak K. Metastatic paraganglioma. Semin Oncol 2010;37:627-637.
Go to original source...
Go to PubMed...
- Zelinka T, Musil Z, Dušková J, et al. Metastatic pheochromocytoma: Does the size and age matter? Eur J Clin Invest 2011: epub ahead of print.
Go to original source...
Go to PubMed...
- Jiang S, Dahia PL. Minireview: The busy road to pheochromocytomas and paragangliomas has a new member, TMEM127. Endocrinology 2011;152:2133-2140.
Go to original source...
Go to PubMed...
- Karasek D, Frysak Z, Pacak K. Genetic testing for pheochromocytoma. Curr Hypertens Rep 2010;12:456-464.
Go to original source...
Go to PubMed...
- Eisenhofer G, Lenders JW, Timmers H, et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem 2011;57:411-420.
Go to original source...
Go to PubMed...
- Zelinka T, Timmers HJ, Kozupa A, et al. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: Specific implications for SDHB gene mutations. Endocr Rel Cancer 2008;15:311-323.
Go to original source...
Go to PubMed...
- van Nederveen FH, Gaal J, Favier J, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009;10:764-771.
Go to original source...
Go to PubMed...
- Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459-1466.
Go to original source...
Go to PubMed...
- Pacák K. Feochromocytom. Praha: Galén, 2008.
- Zelinka T, Eisenhofer G, Pacák K. Pheochromocytoma as a catecholamine producing tumor: Implications for clinical practice. Stress 2007;10:195-203.
Go to original source...
Go to PubMed...
- Zelinka T, Štrauch B, Petrák O, et al. Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. J Hypertens 2005;23:2033-2039.
Go to original source...
- Zelinka T, Štrauch B, Pecen L, et al. Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing's syndrome. J Hum Hypertens 2004;18:107-111.
Go to original source...
Go to PubMed...
- Petrák O, Štrauch B, Zelinka T, et al. Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. Hypertens Res 2010;33:454-459.
Go to original source...
Go to PubMed...
- Holaj R, Zelinka T, Wichterle D, et al. Increased carotid intima-media thickness in patients with pheochromocytoma in comparison to essential hypertension. J Hum Hypertens 2009;23:350-358.
Go to original source...
Go to PubMed...
- Manger WM. An overview of pheochromocytoma. Ann N Y Acad Sci 2006;1073:1-20.
Go to original source...
Go to PubMed...
- Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002;287:1427-1434.
Go to original source...
Go to PubMed...
- Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium, October 2005. Nat Clin Pract Endocrinol Metab 2007;3:92-102.
Go to original source...
Go to PubMed...
- Eisenhofer G, Pacak K, Huynh TT, et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 2011;18:97-111.
Go to original source...
Go to PubMed...
- van Duinen N, Steenvoorden D, Kema IP, et al. Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas. J Clin Endocrinol Metab 2010;95:209-214.
Go to original source...
Go to PubMed...
- Timmers HJ, Gimenez-Roqueplo AP, Mannelli M, et al: Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer 2009;16:391-400.
Go to original source...
Go to PubMed...
- Oishi S, Sato T. Elevated serum neuron-specific enolase in patients with malignant pheochromocytoma. Cancer 1988;61:1167-1170.
Go to original source...
- Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (incidentaloma). Ann Intern Med 2003;138:424-429.
Go to original source...
Go to PubMed...
- Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003;88:2656-2666.
Go to original source...
Go to PubMed...
- Baid SK, Lai EW, Wesley RA, et al. Radiographic contrast infusion and catecholamine release in patients with pheochromocytoma. Ann Intern Med 2009;150:27-32.
Go to original source...
Go to PubMed...
- Ilias I, Chen CC, Carrasquillo JA, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 2008;49:1613-1619.
Go to original source...
Go to PubMed...
- Timmers HJLM, Chen CC, Carrasquillo JA, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009;94:4757-4767.
Go to original source...
Go to PubMed...
- Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007;92:4069-4079.
Go to original source...
Go to PubMed...
- Shen WT, Grogan R, Vriens M, et al. One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy. Arch Surg 2010;145:893-897.
Go to original source...
Go to PubMed...
- Bruynzeel H, Feelders RA, Groenland THN, et al. Risk Factors for hemodynamic instability during surgery for pheochromocytoma. J Clin Endocrinol Metab 2010;95:678-685.
Go to original source...
Go to PubMed...
- Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007;92:3822-3828.
Go to original source...
Go to PubMed...
- Gonias S, Goldsby R, Matthay KK, et al: Phase II study of high-dose [131I] metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009;27:4162-4168.
Go to original source...
Go to PubMed...
- Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 2008;113:2020-2028.
Go to original source...
Go to PubMed...
- Joshua AM, Ezzat S, Asa SL, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 2009;94:5-9.
Go to original source...
Go to PubMed...